SynthesisAlimentary pharmacology & therapeutics2020
Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Synthesis in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.Gastroenterology · 2023Trial
- Positioning of advanced therapies in patients with moderate-to-severe Crohn's disease.Singapore medical journal · 2026Review
- Impact of biologic induction dose and concomitant drugs on anti-drug antibody formation in a pediatric IBD cohort with high Hispanic representation.JPGN reports · 2025Article
- Inflammatory bowel disease in paediatrics: Navigating the old challenges and emerging frontiers.World journal of gastroenterology · 2025Review
- A Case of Hepatosplenic Gamma Delta T Cell Lymphoma With Concomitant Bone Marrow Aplasia Following Azathioprine Therapy, Treatment Course and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice.World journal of gastroenterology · 2025Review
- A Rare Presentation of a Devastating Disease: Hepatosplenic T-Cell Lymphoma in Crohn's Disease Without Thiopurine Exposure.ACG case reports journal · 2025Article
- Sex-Based Disparities in Treatment and Healthcare Utilization in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Thiopurines and risk of lymphoproliferative disorders.Australian prescriber · 2024Article
- Choosing Therapies in Ulcerative Colitis.Journal of the Canadian Association of Gastroenterology · 2024Article
- Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.Current gastroenterology reports · 2023Review
- The Role of Therapeutic Drug Monitoring in Children.Gastroenterology clinics of North America · 2023Review
- The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer.Journal of clinical medicine · 2023Review
- Felty's syndrome.Frontiers in medicine · 2023Review
- Sex- and gender-related differences in inflammatory bowel diseases.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review.Journal of gastrointestinal oncology · 2022Article
- Managing IBD in patients with previous cancers.Frontline gastroenterology · 2022Article
- Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules.Digestive diseases and sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHepatosplenic T-cell lymphoma (HSTCL) is a rare, poorly treatable malignancy associated with therapy for IBD. Current knowledge of HSTCL risk in IBD comes from an era of step-up therapy, before earlier use of biologics or combination therapy was advocated to achieve deep mucosal healing. HSTCL risk among newer biologic classes has also not been evaluated.
aimsTo systematically characterise the association of HSTCL with biologic therapy for IBD.
methodsWe conducted a literature search and query of the Food and Drug Administration Adverse Event Reporting System to summarise HSTCL cases among IBD patients with prior biologic exposure. Demographics and immunosuppression exposure were extracted. Patients were stratified by current regimen (combination therapy, biologic monotherapy or no biologic), and biologic class (anti-TNF, anti-integrin, anti-interleukin 12/23).
resultsSixty-two cases of HSTCL were identified from 2486 abstracts and 181 FDA Adverse Events Reporting System reports. The median age of affected patients was 28 years (range 12-81), and 83.6% were male, 84.7% had Crohn's disease. Five of 62 patients had no reported azathioprine/mercaptopurine exposure. Three patients within the cohort developed HSTCL after exposure to natalizumab, vedolizumab or ustekinumab; all three also had anti-TNF and azathioprine/mercaptopurine exposure. Forty-three of 49 (87.8%) patients with known outcomes died with a median survival of 5 months.
conclusionsConsistent with existing data, almost all identified HSTCL cases among IBD patients on biologic therapy had azathioprine/mercaptopurine exposure, and all cases on patients exposed to biologics had anti-TNF exposure. These data suggest initiating a patient-centred discussion before starting anti-TNF therapy or other biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.